We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
- Authors
Ericsson, C G; Hamsten, A; Nilsson, J; Grip, L; Svane, B; de Faire, U
- Abstract
Bezafibrate has effects on lipid metabolism and haemostatic function. We undertook a double-blind, placebo-controlled intervention trial, the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT), to establish whether bezafibrate (200 mg three times daily) could retard or prevent the progression of atherosclerotic lesions in dyslipidaemic male survivors of myocardial infarction who were younger than 45 years at the time of the event.
- Publication
Lancet (London, England), 1996, Vol 347, Issue 9005, p849
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(96)91343-4